VANTRELA ER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANTRELA ER (VANTRELA ER).
Norepinephrine reuptake inhibitor and alpha-2 adrenergic receptor agonist; increases norepinephrine and serotonin availability in the prefrontal cortex.
| Metabolism | Primarily metabolized via CYP2D6 to 4-hydroxyviloxazine; also minor pathways via CYP3A4 and CYP2C19. |
| Excretion | Primarily renal (70-80% as unchanged drug) with 10-15% biliary/fecal elimination. |
| Half-life | Approximately 24 hours (range 20-30 hours) allowing once-daily dosing; steady state reached in 5-7 days. |
| Protein binding | Approximately 90% bound to albumin and alpha-1 acid glycoprotein. |
| Volume of Distribution | 0.2 L/kg (low Vd indicating limited tissue distribution and high plasma protein binding). |
| Bioavailability | Oral: 85-95% due to extended-release formulation; absolute bioavailability not established for IV route. |
| Onset of Action | Oral: 30-60 minutes for peak effect; therapeutic levels achieved within 2-4 hours. |
| Duration of Action | 24 hours due to extended-release formulation; clinical effect maintained over dosing interval with consistent plasma levels. |
| Molecular Weight | 277.4 |
VANTRELA ER (cialoxine sodium) 250 mg orally once daily with evening meal; maximum dose 500 mg per day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 50% (max 250 mg/day). GFR <30 mL/min: not recommended (no data). |
| Liver impairment | Child-Pugh Class B or C: contraindicated (no safety data). Class A: use normal dosing with caution. |
| Pediatric use | Not approved for patients under 18 years (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment; monitor renal function due to age-related decline; initiate at 125 mg daily if CrCl <60 mL/min. |
| 1st trimester | VANTRELA ER (venlafaxine extended-release) is contraindicated in first trimester due to risk of fetal malformations, particularly cardiac defects. |
| 2nd trimester | Use only if potential benefit justifies risk; may be associated with low birth weight and preterm birth. |
| 3rd trimester | Avoid in third trimester due to risk of persistent pulmonary hypertension of the newborn (PPHN) and neonatal withdrawal syndrome. |
Clinical note
Comprehensive clinical and safety monograph for VANTRELA ER (VANTRELA ER).
| Placental transfer | Venlafaxine and desvenlafaxine cross the placenta. Fetal serum concentrations are approximately 30% of maternal concentrations for venlafaxine and about 60% for desvenlafaxine. |
| Breastfeeding | Venlafaxine and its active metabolite desvenlafaxine are excreted into breast milk. Infant serum levels can be detectable but generally low. Monitor infant for sedation, poor feeding, and irritability. Weigh benefits of breastfeeding against potential risks. |
■ FDA Black Box Warning
May increase the risk of suicidal ideation/suicidal behavior in pediatric/adolescent patients with ADHD; monitor closely for worsening of depression, suicidal thoughts/behaviors, or unusual changes in mood/behavior.
| Serious Effects |
Concurrent use of MAOIs or within 14 days of discontinuing MAOIKnown hypersensitivity to venlafaxine or any excipients
| Precautions | Increased blood pressure and heart rate; suicidal thoughts/behaviors in children/adolescents; activation of mania in patients with bipolar disorder; cardiovascular effects including hypertension, tachycardia, and QT prolongation; priapism; glaucoma; urinary retention; hepatic impairment. |
| Food/Dietary | No specific food interactions; can be taken with or without food. Avoid excessive alcohol intake as it may increase the risk of ketoacidosis. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Risk of major malformations not established but animal studies show increased fetal loss and reduced fetal weight. Second/third trimester: Potential for neonatal opioid withdrawal syndrome with chronic use. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal respiratory status, sedation level, and bowel function. Assess fetal growth and well-being via ultrasound if chronic use. Monitor neonatal for withdrawal symptoms if used near term. |
| Fertility Effects | Animal studies show decreased fertility and increased preimplantation loss at high doses. Human data insufficient; potential for hormonal disruption due to opioid receptor interaction. |
| Clinical Pearls | VANTRELA ER (bexagliflozin) is a sodium-glucose cotransporter 2 inhibitor. Monitor renal function before initiation and periodically; eGFR <30 mL/min/1.73 m2 is a contraindication. Assess volume status in elderly or those on diuretics; risk of hypotension. Do not use for type 1 diabetes or diabetic ketoacidosis (DKA). Ketone monitoring is not necessary but DKA can occur with atypical presentation (euglycemic DKA). Discontinue before scheduled surgery and during acute illness. |
| Patient Advice | Take once daily in the morning with or without food; swallow tablets whole, do not crush or chew. · Stay hydrated to prevent dehydration; report symptoms like dizziness, lightheadedness, or fainting. · Monitor for signs of urinary tract infections (burning, frequency) and genital fungal infections (itching, discharge). · Do not use if you have type 1 diabetes or a history of diabetic ketoacidosis; seek emergency care for symptoms like nausea, vomiting, abdominal pain, or unusual fatigue. · Notify your doctor if you develop nausea, vomiting, or are unable to eat or drink (risk of ketoacidosis). · Ketoacidosis may occur even if blood sugar is normal; stop drug and contact doctor if you feel unwell. · Your doctor may temporarily stop this medicine before surgery or during severe illness. |